Klin Farmakol Farm. 2012;26(2):84-89

Bleeding complications and anticoagulant overdose

Jaromír Gumulec
Ústav klinické hematologie FN Ostrava

Anticoagulant therapy is one of the most widely used treatment modalities. It is the mainstay of prevention and treatment of thrombotic

events. Unjustified omission of adequate anticoagulant prophylaxis is currently seen as a medical error. Bleeding is the most feared complication

of anticoagulant therapy. A certain advantage of heparins and warfarin is the experience with these antithrombotic drugs in a

broad medical population and the existence of a specific antidote that, when needed, allows a rapid reversal of the anticoagulant effect.

Advantages of novel anticoagulant agents (direct and indirect inhibitors of coagulation factors Xa and/or IIa) include a more targeted

anticoagulant effect and a lower risk of drug and food interactions; there are certain drawbacks such as limited options for laboratory

monitoring and the non-existence of a specific antidote. The review article presents the risk of overdose and bleeding complications

with available anticoagulant agents and the current options for the management of these complications.

rivaroxaban.

Keywords: anticoagulant therapy, bleeding, warfarin, heparin, low molecular weight heparin, fondaparinux, refludan, dabigatran,

Published: July 31, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Gumulec J. Bleeding complications and anticoagulant overdose. Klin Farmakol Farm. 2012;26(2):84-89.
Download citation

References

  1. Ageno W, Gallus A S, Wittkowsky A, et al. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(Suppl 2): 44-88. Go to original source... Go to PubMed...
  2. Garcia D A, Baglin T P, Weitz JI, et al. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(Suppl 2): 24-43. Go to original source... Go to PubMed...
  3. Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(Suppl 2): 152-184. Go to original source... Go to PubMed...
  4. Kearon C, Akl E A, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(Suppl 2): 419-494. Go to original source... Go to PubMed...
  5. MacLean S, Mulla S, Akl EA, et al. Patient values and preferences in decision making for antithrombotic therapy: a systematic review: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(Suppl 2): 1-23. Go to original source... Go to PubMed...
  6. Vandvik P O, Lincoff A M, Gore JM, et al. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(Suppl 2): 637-668. Go to original source... Go to PubMed...
  7. Weitz J I, Eikelboom J W, Samama MM. New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(Suppl 2): 120-151. Go to original source... Go to PubMed...
  8. Whitlock R P, Sun J C, Fremes SE, et al. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(Suppl 2): 576-600. Go to original source... Go to PubMed...
  9. You J J, Singer D E, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(Suppl 2): 531-575. Go to original source... Go to PubMed...
  10. Schulman S, Angeras U, Bergqvist D, et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 2010; 8(1): 202-204. Go to original source... Go to PubMed...
  11. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in nonsurgical patients. J Thromb Haemost 2005; 3(4): 692-694. Go to original source... Go to PubMed...
  12. Hirsh J, Bauer K A, Donati MB, et al. Parenteral anticoagulants: American College of Chest Physicians EvidenceBased Clinical Practice Guidelines (8th Edition). Chest 2008; 133(Suppl 6): 141-159. Go to original source... Go to PubMed...
  13. Crowther MA, Warkentin TE. Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. Blood 2008; 111(10): 4871-4879. Go to original source... Go to PubMed...
  14. Crowther MA, Berry LR, Monagle PT, et al. Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin. Br J Haematol 2002; 116(1): 178-186. Go to original source... Go to PubMed...
  15. Makris M, Hough RE, Kitchen S. Poor reversal of low molecular weight heparin by protamine. Br J Haematol 2000; 108(4): 884-885. Go to original source... Go to PubMed...
  16. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133(Suppl 6): 160-198. Go to original source... Go to PubMed...
  17. Schulman S, Beyth RJ, Kearon C, et al. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133(Suppl 6): 257-298. Go to original source... Go to PubMed...
  18. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998; 105(2): 91-99. Go to original source... Go to PubMed...
  19. Crowther MA, Douketis JD, Schnurr T, et al. Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial. Ann Intern Med 2002; 137(4): 251-254. Go to original source... Go to PubMed...
  20. Lankiewicz MW, Hays J, Friedman KD, et al. Urgent reversal of warfarin with prothrombin complex concentrate. J Thromb Haemost 2006; 4(5): 967-970. Go to original source... Go to PubMed...
  21. Pabinger-Fasching I. Warfarin-reversal: results of a phase III study with pasteurised, nanofiltrated prothrombin complex concentrate. Thromb Res 2008; 122(Suppl 2): 19-22. Go to original source... Go to PubMed...
  22. Riess HB, Meier-Hellmann A, Motsch J, et al. Prothrombin complex concentrate (Octaplex) in patients requiring immediate reversal of oral anticoagulation. Thromb Res 2007; 121(1): 9-16. Go to original source... Go to PubMed...
  23. Dentali F, Ageno W, Crowther M. Treatment of coumarin-associated coagulopathy: a systematic review and proposed treatment algorithms. J Thromb Haemost 2006; 4(9): 1853-1863. Go to original source... Go to PubMed...
  24. Dezee KJ, Shimeall WT, Douglas KM, et al. Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis. Arch Intern Med 2006; 166(4): 391-397. Go to original source...
  25. Baker RI, Coughlin PB, Gallus AS, et al. Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. Med J Aust 2004; 181(9): 492-497. Go to original source... Go to PubMed...
  26. Briz M, Talks K, Hanley J, et al. Reversal of warfarin-induced over-anticoagulation with individualized dosing of oral vitamin K: a pilot study. J Thromb Haemost 2010; 8(5): 1123-1125. Go to original source... Go to PubMed...
  27. Evans SJ, Biss TT, Wells RH, et al. Emergency warfarin reversal with prothrombin complex concentrates: UK wide study. Br J Haematol 2008; 141(2): 268-269. Go to original source... Go to PubMed...
  28. Hanley JP. Warfarin reversal. J Clin Pathol 2004; 57(11): 1132-1139. Go to original source... Go to PubMed...
  29. Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(Suppl 2): 326-350. Go to original source... Go to PubMed...
  30. Douketis JD. Perioperative management of antithrombotic therapy: lifting the fog. J Thromb Haemost 2009; 7(12): 1979-1981. Go to original source... Go to PubMed...
  31. Douketis JD, Berger PB, Dunn AS, et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133(Suppl 6): 299-339. Go to original source... Go to PubMed...
  32. Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124(14): 1573-1579. Go to original source... Go to PubMed...




Clinical Pharmacology and Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.